Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics.
The aim of this study was to determine the prevalence of osteopenia in schizophrenic patients with hyperprolactinemia and to identify factors influencing bone density. Our results indicate that low bone mineral density was highly prevalent in a chronic psychiatric population treated with prolactin-elevating antipsychotics. Identified risk factors appear to be age and hyperprolactinemia for both females and males.
Liu-Seifert
Hong
H
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, Indiana 46285, USA.
Kinon
Bruce J
BJ
Ahl
Jonna
J
Lamberson
Shaw
S
D000328:Adult; D000375:Aging / Q000502:physiology*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000097:blood* / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000097:blood / Q000139:chemically induced / Q000453:epidemiology; D011388:Prolactin / Q000097:blood*; D012307:Risk Factors; D012559:Schizophrenia / Q000097:blood* / Q000150:complications* / Q000188:drug therapy
D014150:Antipsychotic Agents; D011388:Prolactin